ヨーロッパの便潜血検査市場 – 業界動向と2030年までの予測

ヨーロッパの便潜血検査市場の分析と規模

便潜血検査市場の成長を牽引する主な要因の 1 つは、ヨーロッパで大腸がんの症例が増加していることです。より正確な診断のために複数の企業が継続的に実施している臨床試験研究が、市場の拡大につながっています。市場は、消費者に直接販売する臨床検査の開発と、オンライン ストアでの便潜血免疫学的検査機器の入手しやすさにも影響を受けています。

ヨーロッパの便潜血検査市場は、2023年から2030年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に5.1％のCAGRで成長し、2030年までに6億8,640万米ドルに達すると分析しています。

市場の定義

便潜血検査 (FOBT) は、便サンプルに隠れた血液を分析するために行われる診断スクリーニング検査です。便潜血検査は、便潜血、免疫測定 FOBT、ヘモカルト、IFOBT、グアヤク塗抹標本検査とも呼ばれます。この検査は主に、大腸がんのスクリーニングや原因不明の貧血の原因分析に利用されています。

便潜血検査市場の動向

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Rising Cases Of Colorectal Cancer in Europe

Colorectal cancer is a disease of the colon or rectum, which are parts of the digestive system. Unlike most cancers, colorectal cancer is often preventable with screening & can be treated when detected early. Most cases of colorectal cancer occur in people ages 45 & older. The disease is increasingly affecting younger people due to unhygienic lifestyles & smoking habits. Colorectal cancers may develop without symptoms. The common symptoms may include blood in or on the stool, persistent unusual bowel movements like constipation or diarrhea, stomach pain, aches or cramps that last longer and losing weight for no reason.

Most colorectal cancers start as abnormal tissue growth, called a polyp, inside the colon or rectum. Doctors can detect polyps with the help of screening tests & can remove them from developing into colorectal cancer. Even if it spreads into nearby lymph nodes, chemotherapy & surgical treatments are effective ways to treat colorectal cancer. Research is going on to learn more about this disease and provide more hope to people with all stages of colorectal cancer.

• Direct-to-consumer Laboratory Testing

Direct-to-consumer laboratory testing is an effective way for users where they can order their corresponding laboratory tests directly from a lab without any healthcare providers. Nowadays, the healthcare industry is shifting towards direct-to-consumer laboratory testing from physician-based lab testing & hence the demand has increased drastically. Most of the patients are focusing on direct-to-consumer based laboratory tests without going through a lengthy in-clinic process, which is fueling the growth of the fecal occult blood tests market.

For the identification of previously unknown medical disorders, the test results are used. The advancements in the field of direct-to-consumer laboratory testing have become crucial to increase patient engagement for better monitoring & screening of existing health conditions. Hence, it is very important for laboratory professionals to upgrade the devices & instruments used in testing laboratories.

• Easy Availability Of Fecal Occult Immunological Test Devices In Online Stores

A fecal occult blood test (FOBT) generally focuses on a stool sample to check for blood. The presence of blood in stool refers that there is bleeding in the digestive tract. The bleeding can be caused by a variety of conditions like Polyps (abnormal growths on the lining of the colon or rectum), Hemorrhoids (swollen veins in the anus or rectum), Diverticulosis (a condition with small pouches in the inside wall of the colon), Ulcers (sores in the lining of the digestive tract), Colitis (a type of inflammatory bowel disease) and Colorectal cancer.

There are a huge number of fecal occult immunological test devices available in the market, and people can buy the kits & devices from various online sites. Hence, it can be a driving factor for the growth of the fecal occult blood tests market.

Opportunities

• Increase in screening procedures

Most government agencies and scientific societies recommend cervical, breast, and colorectal screening because of the burden of these cancers, the availability of screening tests, and the proven efficacy of screening in reducing mortality, as well as incidence, for cervical and colorectal cancers.

The European Community recommends the implementation of population-based screening programs for colorectal cancers. This recommendation is supported by many observational studies showing that organized programs effectively reduce mortality and control the inappropriate use of screening tests.

• Rising technical advancements

A blood test has always been a technology- and data-dependent field. As data and technology potentially revolutionized diagnostic services and had positioned to partner with patients, families, practitioners, researchers, industry leaders, policymakers, and administrators to ensure that humanistic, high-value, ever-improving precise diagnosis remains the central goal for the future of blood test diagnosis.

The use of fecal occult blood testing has expanded to several indications, even though its primary use is for evaluating an occult source of GI blood loss and for home-based kits in colorectal carcinoma screening. One of the most common clinical uses for the hemoccult is for checking a stool specimen for occult bleeding prior to anticoagulation.

Restraints/Challenges

• Change In Consumer Preference Towards Cost-Effective Alternatives

The fecal occult blood test products bear a high cost and usually cannot be afforded by everyone in general. As technology is getting more advanced day by day & there are a number of test alternatives available in the market. Hence, people prefer cost-effective alternatives for fecal occult blood tests. There are various screening programs that often target people with apparently healthy conditions & the number of people using screening services is usually higher than the true number of patients. The FOBT has advantages over colonoscopy in terms of being less costly and easy to perform.

As most of the fecal occult blood test alternatives are available in the market. Hence, people prefer substitutes with lesser cost & more accurate results. Hence, the change in consumer preference toward cost-effective alternatives may restrain the market growth in the forecast period.

• Low efficiency

The fecal occult blood test is not always accurate and could show a negative test result when cancer is present and have a false-negative result if cancer or polyps do not bleed.

The test could show a positive result when the person has no cancer (false-positive result) or have bleeding from other sources, such as a stomach ulcer, hemorrhoid, or even blood swallowed from the mouth or nose.

Post-COVID-19 Impact on the Fecal Occult Blood Tests Market

The COVID-19 pandemic had a great impact on the fecal occult blood test industries. Trade groups in colorectal cancer and gastrointestinal bleeding diagnostic products sector claim that the Europe supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the fecal occult blood tests market. Sales of test products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care and fecal occult blood test instruments.

Recent Developments

• In November 2022, Eiken Chemical Co, Ltd. had launched the fully automated fecal immunochemical test/ Faecal Calprotectin Analyzer “OC-SENSOR Ceres.” This has helped the company to establish its product Europely
• In January 2022, Boditech Med Inc. announced that it had signed a USD19.2 Million supply agreement with A. Menarini Diagnostics to accelerate its product portfolio. This helps the organization in generating revenue

Europe Fecal Occult Blood Tests Market Scope

The Europe fecal occult blood tests market is segmented into four notable segments based on test type, application, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Test Type

• Lateral Flow Immuno-FOB Test Kits
• Immuno-FOB Agglutination Test Kits
• Immuno-FOB ELISA Test Kits
• Guaiac FOB Stool Tests
• Flushable Reagent Pad Or Tissue
• Others

On the basis of test type, the Europe fecal occult blood tests market is segmented into lateral flow immuno-FOB test kits, immuno-FOB agglutination test kits, immuno-FOB ELISA test kits, guaiac FOB stool tests, flushable reagent pad or tissue, and others.

Application

• Colorectal Cancer Screening
• Concern For Gastrointestinal Bleeding
• Polyps
• Diverticulosis
• Ulcers
• Haemorrhoids
• Colitis
• Anemia
• Others

On the basis of application, the Europe fecal occult blood tests market is segmented into Colorectal Cancer Screening, Concern for gastrointestinal bleeding, Polyps, Diverticulosis, Ulcers, Haemorrhoids, Colitis, Anemia, and others.

End User

• Diagnostic Laboratories
• Hospitals
• Specialty Clinics
• Others

エンドユーザーに基づいて、ヨーロッパの便潜血検査市場は、診断研究所、病院、専門クリニック、その他に分類されます。

流通チャネル

• 直接入札
• 小売販売
• 電子商取引
• その他

流通チャネルに基づいて、ヨーロッパの便潜血検査市場は、直接入札、小売販売、電子商取引、その他に分類されます。

便潜血検査市場の地域分析/洞察

便潜血検査市場が分析され、上記のように国、検査タイプ、アプリケーション、エンドユーザー、流通チャネル別に市場規模の洞察と傾向が提供されます。

ヨーロッパの便潜血検査市場は、ロシア、スペイン、トルコ、ドイツ、イタリア、イギリス、フランス、ベルギー、スイス、オランダ、その他のヨーロッパ諸国で構成されています。

ドイツは、ポイントオブケア診断への傾向が高まっているため、ヨーロッパの便潜血検査市場を支配すると予想されています。便潜血検査製品の需要の増加と業界における研究開発活動の増加も、予測期間中に市場を牽引すると予想されます。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。

競争環境と欧州便潜血検査市場シェア分析

便潜血検査市場の競争状況は、競合他社による詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、ヨーロッパでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、ヨーロッパの便潜血検査市場への会社の焦点にのみ関連しています。

この市場で活動している主要企業としては、Biopanda Reagents Ltd.、ulti med Products (Deutschland) GmbH、CERTEST BIOTEC.、Alfa Scientific Designs, Inc.、Biohit Oyj、Hangzhou Clongene Biotech Co., Ltd.、Wondfo.、PRIMA Lab SA、Boditech Med Inc.、Epitope Diagnostics, Inc.、Accuquik Test Kits、Aidian、Apacor Limited、Quidel Corporation.、Eurolyser Diagnostica GmbH、Siemens Healthcare GmbH、Eiken Chemical Co., Ltd. などがあります。

SKU-69790